A lab worker boxes up test tubes of patient samples in a virology research labs | Geert Vanden Wijngaert | Bloomberg
A lab worker boxes up test tubes of patient samples in a virology research labs | Geert Vanden Wijngaert | Representational image | Bloomberg File Photo
Text Size:

New Delhi: US-based pharmaceutical firm Moderna has completed phase one of the clinical trials of a Covid-19 vaccine based on mRNA technology.

The mRNA is a molecule that genetically encodes a set of instructions, based on which cells make proteins and send them to various parts of the body. Vaccines based on mRNA technology take advantage of normal biological processes of the body to create the desired therapeutic effect.

The vaccine has shown positive results in the first phase of the human trial conducted on 45 patients. All vaccine recipients are safe and eight of them produced more antibodies against coronavirus than the infected patients did.

These vaccines also offer potential advantages such as efficacy, speed of development and production scalability. According to Ingmar Hoerr, head of the German biopharmaceutical company CureVac, “One gram of mRNA vaccine can immunise 1 million people.”

Moderna has started phase two of the trial and this will be the first mRNA-based vaccine to enter phase three, if it does so, by July. These encouraging developments increased Moderna’s share price from $18.50 to nearly $87, bringing fortunes to an MIT Professor Bob Langer who holds 3.2 per cent of the shares in the company.


Also read: Vaccine developers like Moderna need to take their time


Other frontrunners in the race 

US President Donald Trump has instituted ‘Operation Warp Speed’ for early vaccine development.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

Chinese companies’ vaccines are progressing too. Sinovec Biotech’s vaccine, based on a chemically inactivated version of the virus, successfully protected rhesus macaques, a monkey species, from Covid-19. Human trials of the vaccine began on 16 April.

Oxford University’s vaccine based on adenovirus showed mixed results. An experiment revealed that vaccinated monkeys did get infected from Covid-19 but did not get pneumonia, lessening the intensity of the disease. Oxford University has also partnered with AstraZeneca for distributing their vaccine


Also read: Oxford’s Covid vaccine, being tested on humans in UK, fails to prevent infection in monkeys


Vaccine progress in India

Serum Institute of India has started mass production of Oxford University’s vaccine in anticipation of it passing trials, thus India can play a decisive role in vaccine distribution.

The Indian Council of Medical Research is also collaborating with Bharat Biotech Limited, a Biosafety level three lab, to develop a coronavirus vaccine.

Thirdly, INOVIO, a US pharmaceutical firm, is in negotiation with some Indian companies to start producing DNA-based vaccine, which use the electroporation method to inject DNA into cells.

Chances of vaccine 

According to UK Prime Minister Boris Johnson, we may never have a Covid-19 vaccine. However, Dr Anthony Fauci, director of National Institute of Allergy & Infectious diseases in US said that as the human body has been able to produce antibodies against the Covid-19 virus, he believes that it is highly likely that a vaccine can be developed.

Watch the latest episode of CTC here:

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here